Acromegaly 0 10 0 10 B-chronic_disease
patients 11 19 11 19 O
on 20 22 20 22 O
Pegvisomant 23 34 23 34 B-treatment
monotherapy 35 46 35 46 I-treatment
with 47 51 47 51 O
normal 52 58 52 58 O
or 59 61 59 61 O
elevated 62 70 62 70 O
IGF-1 71 76 71 76 B-clinical_variable
levels 77 83 77 83 I-clinical_variable

Acromegaly 0 10 84 94 B-chronic_disease
patients 11 19 95 103 O
on 20 22 104 106 O
SRL 23 26 107 110 B-treatment
monotherapy 27 38 111 122 I-treatment
with 39 43 123 127 I-treatment
normal 44 50 128 134 I-treatment
or 51 53 135 137 I-treatment
elevated 54 62 138 146 I-treatment
IGF-1 63 68 147 152 I-treatment
levels 69 75 153 159 I-treatment

Acromegaly 0 10 160 170 B-chronic_disease
patients 11 19 171 179 O
on 20 22 180 182 O
combination 23 34 183 194 B-treatment
therapy 35 42 195 202 I-treatment
with 43 47 203 207 O
maximum 48 55 208 215 O
doses 56 61 216 221 O
of 62 64 222 224 O
SRL 65 68 225 228 B-treatment
and 69 72 229 232 O
Pegvisomant 73 84 233 244 B-treatment
( 85 86 245 246 O
daily 86 91 246 251 O
or 92 94 252 254 O
weekly 95 101 255 261 O

Acromegaly 0 10 262 272 B-chronic_disease
patients 11 19 273 281 O
who 20 23 282 285 O
are 24 27 286 289 O
at 28 30 290 292 O
least 31 36 293 298 O
3 37 38 299 300 B-lower_bound
months 39 45 301 307 I-lower_bound
post 46 50 308 312 B-treatment
surgery 51 58 313 320 I-treatment
, 58 59 320 321 O
who 60 63 322 325 O
are 64 67 326 329 O
/ 67 68 329 330 O
are 68 71 330 333 O
not 72 75 334 337 O
receiving 76 85 338 347 O
adjuvant 86 94 348 356 B-treatment
medical 95 102 357 364 I-treatment
therapy 103 110 365 372 I-treatment

Acromegaly 0 10 373 383 B-chronic_disease
patients 11 19 384 392 O
who 20 23 393 396 O
have 24 28 397 401 O
received 29 37 402 410 O
SRL 38 41 411 414 B-treatment
and 42 45 415 418 O
dopamine 46 54 419 427 B-treatment
agonist 55 62 428 435 I-treatment
therapy 63 70 436 443 I-treatment
, 70 71 443 444 O
after 72 77 445 450 O
a 78 79 451 452 O
6 80 81 453 454 B-upper_bound
week 82 86 455 459 I-upper_bound
washout 87 94 460 467 O
period 95 101 468 474 O
of 102 104 475 477 O
the 105 108 478 481 O
dopamine 109 117 482 490 O
agonist 118 125 491 498 O

Newly 0 5 499 504 O
diagnosed 6 15 505 514 O
patients 16 24 515 523 O
with 25 29 524 528 O
acromegaly 30 40 529 539 B-chronic_disease
who 41 44 540 543 O
have 45 49 544 548 O
not 50 53 549 552 O
had 54 57 553 556 O
surgery 58 65 557 564 B-treatment
or 66 68 565 567 O
medical 69 76 568 575 B-treatment
therapy 77 84 576 583 I-treatment

The 0 3 584 587 O
patient 4 11 588 595 O
had 12 15 596 599 O
pituitary 16 25 600 609 B-treatment
surgery 26 33 610 617 I-treatment
within 34 40 618 624 O
3 41 42 625 626 B-upper_bound
months 43 49 627 633 I-upper_bound
prior 50 55 634 639 I-upper_bound
to 56 58 640 642 O
study 59 64 643 648 O
entry 65 70 649 654 O

The 0 3 655 658 O
patient 4 11 659 666 O
had 12 15 667 670 O
radiotherapy 16 28 671 683 B-treatment
within 29 35 684 690 O
12 36 38 691 693 B-upper_bound
months 39 45 694 700 I-upper_bound
prior 46 51 701 706 I-upper_bound
to 52 54 707 709 O
study 55 60 710 715 O
entry 61 66 716 721 O

The 0 3 722 725 O
patient 4 11 726 733 O
harbors 12 19 734 741 O
a 20 21 742 743 O
macroadenoma 22 34 744 756 B-cancer
with 35 39 757 761 O
visual 40 46 762 768 O
field 47 52 769 774 O
defects 53 60 775 782 O
due 61 64 783 786 O
to 65 67 787 789 O
chiasmatic 68 78 790 800 O
compression 79 90 801 812 O

The 0 3 813 816 O
patient 4 11 817 824 O
has 12 15 825 828 O
any 16 19 829 832 O
mental 20 26 833 839 B-chronic_disease
condition 27 36 840 849 I-chronic_disease
rendering 37 46 850 859 O
the 47 50 860 863 O
patient 51 58 864 871 O
unable 59 65 872 878 O
to 66 68 879 881 O
understand 69 79 882 892 O
the 80 83 893 896 O
nature 84 90 897 903 O
, 90 91 903 904 O
scope 92 97 905 910 O
, 97 98 910 911 O
and 99 102 912 915 O
possible 103 111 916 924 O
consequences 112 124 925 937 O
of 125 127 938 940 O
the 128 131 941 944 O
study 132 137 945 950 O
, 137 138 950 951 O
and/or 139 145 952 958 O
evidence 146 154 959 967 O
of 155 157 968 970 O
an 158 160 971 973 O
uncooperative 161 174 974 987 O
attitude 175 183 988 996 O

The 0 3 997 1000 O
patient 4 11 1001 1008 O
has 12 15 1009 1012 O
clinically 16 26 1013 1023 O
significant 27 38 1024 1035 O
hepatic 39 46 1036 1043 B-chronic_disease
abnormalities 47 60 1044 1057 I-chronic_disease
and/or 61 67 1058 1064 O
aspartate 68 77 1065 1074 B-clinical_variable
aminotransferase 78 94 1075 1091 I-clinical_variable
( 95 96 1092 1093 I-clinical_variable
AST 96 99 1093 1096 I-clinical_variable
) 99 100 1096 1097 I-clinical_variable
and/or 101 107 1098 1104 O
alanine 108 115 1105 1112 B-chronic_disease
aminotransferase 116 132 1113 1129 I-chronic_disease
( 133 134 1130 1131 I-chronic_disease
ALT 134 137 1131 1134 I-chronic_disease
) 137 138 1134 1135 I-chronic_disease
above 139 144 1136 1141 O
3 145 146 1142 1143 B-lower_bound
times 147 152 1144 1149 I-lower_bound
the 153 156 1150 1153 I-lower_bound
upper 157 162 1154 1159 I-lower_bound
limit 163 168 1160 1165 I-lower_bound
of 169 171 1166 1168 I-lower_bound
normal 172 178 1169 1175 I-lower_bound
at 179 181 1176 1178 O
the 182 185 1179 1182 O
baseline 186 194 1183 1191 O
visit 195 200 1192 1197 O

The 0 3 1198 1201 O
patient 4 11 1202 1209 O
has 12 15 1210 1213 O
had 16 19 1214 1217 O
appropriate 20 31 1218 1229 O
dynamic 32 39 1230 1237 O
testing 40 47 1238 1245 O
of 48 50 1246 1248 O
the 51 54 1249 1252 O
pituitary 55 64 1253 1262 O
axis 65 69 1263 1267 O
and 70 73 1268 1271 O
, 73 74 1271 1272 O
if 75 77 1273 1275 O
applicable 78 88 1276 1286 O
, 88 89 1286 1287 O
is 90 92 1288 1290 O
receiving 93 102 1291 1300 O
appropriate 103 114 1301 1312 O
hormone 115 122 1313 1320 B-treatment
replacement 123 134 1321 1332 I-treatment
therapy 135 142 1333 1340 I-treatment

